| 徐 鹤,林海龙,颜陪实,王晓旭,李仁全.氨氯地平联合阿托伐他汀钙对原发性高血压患者血清Fractalkine与内皮功能的影响[J].,2019,19(24):4764-4767 |
| 氨氯地平联合阿托伐他汀钙对原发性高血压患者血清Fractalkine与内皮功能的影响 |
| The Effects on Amlodipine Combine with Atorvastatin on Serum Fractalkine and Endothelial Function in Primary Hypertension Patients |
| 投稿时间：2019-07-23 修订日期：2019-08-18 |
| DOI：10.13241/j.cnki.pmb.2019.24.038 |
| 中文关键词: 氨氯地平 阿托伐他汀钙 原发性高血压 |
| 英文关键词: Amlodipine Atorvastatin Primary hypertension |
| 基金项目:辽宁省卫生发展研究中心立项课题(2014SDWSF225) |
|
| 摘要点击次数: 734 |
| 全文下载次数: 467 |
| 中文摘要: |
| 摘要 目的：研究氨氯地平联合阿托伐他汀钙对原发性高血压患者血清Fractalkine与内皮功能的影响。方法：选择2017年2月至2018年2月在我院接受治疗的原发性高血压患者106例，按照随机数字表随机分为对照组和观察组，对照组使用氨氯地平治疗，观察组以对照组为基础联合阿托伐他汀钙治疗，两组患者均治疗2个月。比较两组临床疗效，观察治疗前后两组血压、内皮功能（ET-1、NO、 FMO）及血清Fractalkine水平变化。结果：治疗后，观察组总有效率为94.33%，明显高于对照组81.13%（P<0.05）；治疗后，观察组收缩压及舒张压水平为（118.43±15.72）mmHg、（81.32±6.87）mmHg，明显低于对照组（126.71±17.38）mmHg、（86.18±5.29）mmHg（P<0.05）；观察组血清Fractalkine、ET-1水平为（217.81±76.62）pg/mL、（53.82±6.73）ng/L，明显低于对照组（282.17±83.24）pg/mL、（65.14±7.92）ng/L（P<0.05）；观察组血清NO、FMO水平为（21.07±1.95）μmol/L、（13.94±0.82）%，均明显高于对照组（18.04±2.02）μmol/L、（11.28±1.04）%，比较差异显著（P<0.05）。结论：氨氯地平联合阿托伐他汀钙治疗原发性高血压可显著提高临床疗效，同时可显著降低血清FKN水平，改善其内皮功能。 |
| 英文摘要: |
| ABSTRACT Objective: To study the effect of amlodipine combined with atorvastatin on serum Fractalkine and endothelial function in primary hypertension patients. Methods: 106 patients of primary hypertension who received therapy from February 2017 to February 2018 in our hospital were selected as research objects, according to random number table were randomly divided into control group and observation group, the control group was treated with amlodipine, while the observation group was treated with amlodipine combine with atorvastatin, two groups of patients were 2 months treatment. The clinical efficacy, the blood pressure, endothelial function (et-1, NO, FMO) and serum Fractalkine levels of the two groups were observed before and after treatment. Results: After treatment, the total effective rate of the observation group was 94.33%, higher than that of the control group was 81.13%(P<0.05). After treatment, the Systolic and diastolic pressures in Observation group was less than the control group of[(118.43±15.72)vs(126.71±17.38) mmHg, (81.32±6.87)vs(86.18±5.29) mmHg](P<0.05). The serum levels of Fractalkine and et-1 in the observation group was less than the control group of[(217.81±76.62)vs(282.17±83.24) pg/mL, ( 53.82±6.73)vs(65.14±7.92) ng/L]（P<0.05）. Serum levels of NO and FMO in Observation group was higher than the control group of[(21.07±1.95)vs(18.04±2.02) μmol/L, (13.94±0.82)vs(11.28±1.04)%], and the comparison difference was significant (P<0.05). Conclusion: Amlodipine combine with atorvastatin in the treatment of primary hypertension can significantly improve the clinical efficacy, significantly reduce serum FKN level and improve its endothelial function. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
